Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer, August 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 261 articles:
HTML format


 

Single Articles

  1. OGUNKEYE J, Shkolyar E, Mach KE, Prendiville S, et al
    Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection.
    Eur Urol Focus. 2026 Jul 31:S2405-4569(26)00097.
    PubMed    
    Abstract available

  2. USUI K, Ito H, Muraoka K, Noto N, et al
    Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Variant Histology Bladder Cancer: A Multi-institutional Propensity Score-Matched Analysis.
    Clin Genitourin Cancer. 2026;24:102618.
    PubMed    
    Abstract available

  3. GAO S, Jiang P, Liu X, Wang J, et al
    Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer.
    Biosens Bioelectron. 2026;312:119076.
    PubMed    
    Abstract available

  4. BOGALE DE
    Activation of the PI3K/AKT/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance.
    Cancer Treat Res Commun. 2026;48:101340.
    PubMed    
    Abstract available

  5. ABDULLAH OR, Short K, Alomari LHF, Ignatowicz A, et al
    Venous thromboembolism in urothelial bladder cancer - scope of the problem and patients' perspectives: VTE-UBC.
    Wiad Lek. 2026;79:1169-1178.
    PubMed    
    Abstract available

  6. ZHONG C, Masters M, Donzella SM, Bliwise DL, et al
    Risk of bladder cancer among male participants reporting nocturia in the Cancer Prevention Study-II.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed    
    Abstract available

  7. NIEGISCH G, Grunewald C
    [Perioperative treatment of muscle-invasive bladder cancer : Current treatment concepts].
    Urologie. 2026 Jul 31. doi: 10.1007/s00120-026-02900.
    PubMed    
    Abstract available

  8. MO Z, Gai S, Qin X, Meng D, et al
    Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].
    Int J Biol Macromol. 2026 Jul 30:153654. doi: 10.1016/j.ijbiomac.2026.153654.
    PubMed    


  9. VERMA GK, Saini D, Chaudhary PK, Saha S, et al
    Association between heavy metal exposure and epigenetic modifications in patients with urinary bladder cancer.
    Gene. 2026 Jul 30:150330. doi: 10.1016/j.gene.2026.150330.
    PubMed    
    Abstract available

  10. CHEVILLE JC, Tekin B, Orme JJ, Jimenez RE, et al
    ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy.
    Hum Pathol. 2026 Jul 30:106217. doi: 10.1016/j.humpath.2026.106217.
    PubMed    
    Abstract available

  11. HENDRI AZ, Robert R, Febriyanto T, Liliana B, et al
    Prognostic significance of TOP2A expression in bladder cancer: Systematic review and meta-analysis.
    Can Urol Assoc J. 2026 Jul 20. doi: 10.5489/cuaj.9572.
    PubMed    
    Abstract available

  12. SAYED U, Basheer NM, H M, Nayak PP, et al
    Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches.
    Cell Biol Int. 2026;50:e70191.
    PubMed    
    Abstract available

  13. JIN J, Jin Y, Zhang R, Li Y, et al
    A novel quinoline and manganese-based carbon monoxide-releasing molecule for intravesical therapy of bladder cancer.
    Br J Pharmacol. 2026 Jul 30. doi: 10.1111/bph.70614.
    PubMed    
    Abstract available

  14. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Comparison of 5-aminolevulinic acid-induced hypotension of extending the oral administration period during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Jul 29:105591.
    PubMed    
    Abstract available

  15. GU T, Gunelli R, Chen T, Wang C, et al
    Robotic-assisted intracorporeal radical cystectomy with modified ileal conduit reduces ureteroileal anastomotic stenosis risk: a comparative study with laparoscopic surgery.
    Ann Med. 2026;58:2703361.
    PubMed    
    Abstract available

  16. GAN L, Wu J, Li Z, Cao H, et al
    Intra-corporeal robot-assisted versus open radical cystectomy: a meta-analysis.
    World J Urol. 2026;44:531.
    PubMed    
    Abstract available

  17. SALAH IBRAHIM A, Gamal DA, Hadia A, Hasaballah A, et al
    Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.
    Asian Pac J Cancer Prev. 2026;27:2571-2580.
    PubMed    
    Abstract available

  18. DA SILVA IM, Rocha LMO, de Andrade QG, de Lima LVA, et al
    Telomere stability pathway genes as predictors of susceptibility and prognosis in urothelial bladder cancer: review and bioinformatics analyses.
    J Toxicol Environ Health B Crit Rev. 2026.
    PubMed    
    Abstract available

  19. ANTONELLI L, Afferi L, Del Giudice F, Bologna E, et al
    Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2026 Jul 28:S2405-4569(26)00155.
    PubMed    
    Abstract available

  20. SUARTZ CV, Huber IMT, Brito PHS, de Lima RD, et al
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies.
    Clin Oncol (R Coll Radiol). 2026;57:104281.
    PubMed    
    Abstract available

  21. DE MIGUEL-GARCIA G, Ruiz de Porras V, Font-Moron M, Font A, et al
    Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification.
    Biomed Pharmacother. 2026;202:119807.
    PubMed    
    Abstract available

  22. WANG B, Zou J, Gao L, Lou F, et al
    Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.
    Asia Pac J Oncol Nurs. 2026;13:101001.
    PubMed    
    Abstract available

  23. LAINEZ N, Martinez-Kareaga M, Sagastibeltza-Marinalarena N, Sanchez M, et al
    Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.
    ESMO Real World Data Digit Oncol. 2026;13:100732.
    PubMed    
    Abstract available

  24. XU J, Xiong Y, Liu C, Sun J, et al
    Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.
    Mol Biomed. 2026;7:119.
    PubMed    
    Abstract available

  25. HAGE L, Chakra MA, O'Donnell MA, Userovici M, et al
    Clinical patterns and pathogenesis of bladder leiomyoma: a multicenter observational study.
    World J Urol. 2026;44:526.
    PubMed    
    Abstract available

  26. TANAKA T, Oriyama T, Yamamoto T, Kimura S, et al
    Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.
    Support Care Cancer. 2026;34:808.
    PubMed    
    Abstract available

  27. LUO Y, Liu X, Zhu S, Lin P, et al
    Clonal evolution and stromal crosstalk drive an invasive epithelial program in bladder cancer.
    Front Cell Dev Biol. 2026;14:1809774.
    PubMed    
    Abstract available

  28. LIU T, Li W, Yin Q, Liu D, et al
    Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.
    Pharmaceuticals (Basel). 2026;19:1116.
    PubMed    
    Abstract available

  29. CANCERS EDITORIAL OFFICE
    Expression of Concern: Park et al. Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers 2019, 11, 1494.
    Cancers (Basel). 2026;18:2357.
    PubMed    
    Abstract available

  30. SALA-GONZALEZ N, Chekhun S, Fina C, Vilaseca M, et al
    Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.
    Cancers (Basel). 2026;18:2269.
    PubMed    
    Abstract available

  31. MUKHERJEE N, Ji N, Hassouneh Z, Furman J, et al
    Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy.
    Cancers (Basel). 2026;18:2267.
    PubMed    
    Abstract available

  32. PEREZ M, Lozano JJ, Ingelmo-Torres M, Domenech M, et al
    Correction: Perez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.
    Biomedicines. 2026;14:1604.
    PubMed    
    Abstract available

  33. GIMALOVA G, Gilyazova I, Khusnutdinova E, Pavlov V, et al
    SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance.
    Curr Issues Mol Biol. 2026;48:662.
    PubMed    
    Abstract available

  34. UGUR R, Demiriz B, Nisli O, Keskin ET, et al
    Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non-Muscle-Invasive Bladder Cancer?
    Ann Surg Oncol. 2026 Jul 27. doi: 10.1245/s10434-026-20268.
    PubMed    
    Abstract available

  35. TYSON MD 2ND, Nam JK, Joshi SS, Uchio EM, et al
    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
    Lancet Oncol. 2026;27:983-993.
    PubMed    
    Abstract available

  36. AKPINAR C, Aydog E, Sahin B, Gulsen M, et al
    Contemporary Trends in the Surgical and Systemic Management of Muscle-Invasive Bladder Cancer: Insights From a Nationwide Multicenter Cohort in Turkey Over 2 Decades.
    Clin Genitourin Cancer. 2026;24:102612.
    PubMed    
    Abstract available

  37. ALI M, Soliman SE, Eldeeb TS, Aboeleuon E, et al
    Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP.
    Mol Biol Rep. 2026;53:1281.
    PubMed    
    Abstract available

  38. BEDKE J, Eccleston A, Unsworth M, Brinkmann J, et al
    Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.
    Future Oncol. 2026 Jul 27:1-14. doi: 10.1080/14796694.2026.2696928.
    PubMed    
    Abstract available

  39. WANG W, Li D, Liu J, Li L, et al
    Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.
    J Med Chem. 2026 Jul 27. doi: 10.1021/acs.jmedchem.6c01714.
    PubMed    
    Abstract available

  40. ZHANG Y, Shi X, Yuan Y, Gao X, et al
    MoN/Au/cTAT Boosted Sonochemotherapy Post-Intravesical Instillation in Bladder Cancer.
    Small. 2026 Jul 27:e11210. doi: 10.1002/smll.202511210.
    PubMed    
    Abstract available

  41. FREY LJ, Lache N, Fischer ND, Rolz N, et al
    Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
    Oncol Res. 2026;34:14.
    PubMed    
    Abstract available

  42. WANG YD, Lai YL, Liu CH, Su YT, et al
    Epigenomics-Guided Multi-Omics Integration Uncovers a Lipid-Metabolic Signature with Translational Utility in Bladder Cancer.
    Comput Struct Biotechnol J. 2026;35:0139.
    PubMed    
    Abstract available

  43. ISHIGAMI Y, Takahashi M, Nakatsukasa H, Shibano M, et al
    Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.
    Immunotherapy. 2026;18.
    PubMed    
    Abstract available

  44. TYAGI B, Tyagi A, Vashishta M, Tyagi N, et al
    Integrated analyses of the microbiome, metabolome, and spatial transcriptomics reveal sex-dependent bladder vulnerability to chronic inorganic arsenic.
    J Hazard Mater. 2026;514:142653.
    PubMed    
    Abstract available

  45. CAO S, Chen Z, Wang S, Zhou Q, et al
    Arsenic induced deubiquitination modification of PLCE1 in a de-SUMO-dependent manner to affect malignant behavior in bladder epithelial cells.
    J Hazard Mater. 2026;514:142786.
    PubMed    
    Abstract available

  46. ZHU A, Singh Z, Holt SK, Schade GR, et al
    Impact of low levels of arsenic in drinking water with incident urologic cancers in Washington state.
    J Hazard Mater. 2026;514:142671.
    PubMed    
    Abstract available

  47. ZHU Y, Hu Q, Zhang R, Zhang G, et al
    Advancements in Endoscopic Optical Coherence Tomography for Urothelial Carcinoma: Research Progress and Clinical Applications.
    Curr Med Imaging. 2026;22:e15734056434411.
    PubMed    
    Abstract available

  48. DIANA P, Paciotti M, Frego N, Gallioli A, et al
    Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics.
    Eur Urol Focus. 2026;12:377-382.
    PubMed    
    Abstract available

  49. TILKI B, Guler OC, Demirhan B, Hurmuz P, et al
    Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience.
    Clin Transl Radiat Oncol. 2026;60:101246.
    PubMed    
    Abstract available

  50. ELEFTHERIOU C, Zhao Y, Lami M, Boaz RJ, et al
    Comparison of postoperative and early oncological outcomes of open versus robotic radical cystectomy.
    J Robot Surg. 2026;20:808.
    PubMed    
    Abstract available

  51. DOLEK EK, Biyikoglu M, Cayan S, Senel S, et al
    The Effect of Intravesical Bacillus Calmette-Guerin Treatment on Sexual Functions and Mental Health in Male and Female Patients Diagnosed with Non-Muscle Invasive Bladder Cancer.
    Urol Res Pract. 2026;52:1-8.
    PubMed    
    Abstract available

  52. XU J, Huang Y, Ni G, Huang Y, et al
    Hemostatic Efficacy and Clinical Outcomes of Radiotherapy in Older Adult Patients With Advanced Bladder Cancer and Hematuria Unsuitable for Standard Treatment.
    Med Sci Monit. 2026;32:e953113.
    PubMed    
    Abstract available

  53. DEZA I, de Lacy Costello B, Drabinska-Fois N, White P, et al
    Urinary volatilomics using liquid-liquid extraction and gas chromatography-mass spectrometry (GC-MS) combined with machine learning algorithms as a tool for diagnosis and surveillance of urothelial bladder cancer.
    BJC Rep. 2026;4:42.
    PubMed    
    Abstract available

  54. SFORZA S, Lubbersmeyer F, Mari A
    Prognostic Factors After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: From Prognostication to Patient Selection.
    Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00200-2. doi: 10.1016/j.euo.2026.
    PubMed    


  55. ST-LAURENT MP, Eigl BJ, Tyldesley S, Yuan R, et al
    NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.
    Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00198-7. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available

  56. YANG X, Cai L, Wang C, Tan Z, et al
    The Prognostic Role of HER2 Expression in Patients With Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102624.
    PubMed    
    Abstract available

  57. XU Z, Wang X
    Intracorporeal urinary diversion during robot-assisted radical cystectomy: a bibliometric and visualization analysis of research evolution, evidence landscape, learning curves, and clinical outcomes.
    J Robot Surg. 2026;20:806.
    PubMed    
    Abstract available

  58. IKEHATA Y, Nishiyama N, Miyake M, Nishimura N, et al
    Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guerin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).
    Jpn J Clin Oncol. 2026 Aug 7:hyag124. doi: 10.1093.
    PubMed    
    Abstract available

  59. TYSON MD 2ND, Choudry MM, McKee C, Kalaria S, et al
    Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.
    JU Open Plus. 2026;4:e00085.
    PubMed    
    Abstract available

  60. DONG X, Chen Z, Chen Y, Xiao Z, et al
    Mechanical stress, metabolic reprogramming and stromal remodeling: an emerging paradigm in the bladder cancer mechano-micro-environment.
    Front Genet. 2026;17:1896399.
    PubMed    
    Abstract available

  61. GOH NS
    Presumed Simultaneous Intraocular and Extraocular BCG-osis as a Complication of Intravesical Bacillus Calmette-Guerin Treatment for Non-Muscle-Invasive Bladder Cancer: A Case Report.
    Cureus. 2026;18:e114020.
    PubMed    
    Abstract available

  62. DIAO X, Che B, Zhai J, Shao B, et al
    Decoding the temporal dimension of innate immunity in intravesical BCG therapy.
    Front Immunol. 2026;17:1904049.
    PubMed    
    Abstract available

  63. SAAD A, Daraan FM, Barghouth I, Sleiay M, et al
    Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.
    Case Rep Oncol Med. 2026;2026:7517129.
    PubMed    
    Abstract available

  64. HENSLEY PJ, Teoh JYC, Li R, Gupta S, et al
    Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.
    Nat Rev Urol. 2026 Aug 5. doi: 10.1038/s41585-026-01179.
    PubMed    
    Abstract available

  65. SAAD MA, Antari A, Taleb I, El Omri S, et al
    Bacillus Calmette-Guerin (BCG) with or without immune checkpoint blockade in BCG-naive high-risk non-muscle-invasive bladder cancer: A systematic review and reconstructed individual patient data meta-analysis.
    Crit Rev Oncol Hematol. 2026;227:105510.
    PubMed    
    Abstract available

  66. KIEBACH J, Kamps CSAD, Wesselink E, Aben KKH, et al
    Lifestyle and dietary inflammation scores and risks of recurrence and progression among patients with non-muscle invasive bladder cancer.
    Nutrition. 2026;151:113354.
    PubMed    
    Abstract available

  67. ZUO J, Tan Y, Mu Z, Dong Y, et al
    Assembly-formed bioorthogonal chimeric artificial receptors enable high-contrast fluorescence imaging of tumors.
    Sci Adv. 2026;12:eaed9403.
    PubMed    
    Abstract available

  68. GAOL LML, Prabaningrum YSK, Andy, Swity AF, et al
    Atypical desmoplastic small round cell tumor (DSRCT) mimicking muscle-invasive bladder cancer (MIBC) in a child: Surgical approach using ileal diversion.
    Radiol Case Rep. 2026;21:4398-4404.
    PubMed    
    Abstract available

  69. ZHOU L, Zhu J, Liu Y, Xu B, et al
    Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.
    Mol Carcinog. 2026 Aug 5. doi: 10.1002/mc.70162.
    PubMed    
    Abstract available

  70. CHEN Y, Jiang Y, Yang Z, Jing M, et al
    LAMC2(+) Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis.
    Cancer Sci. 2026 Aug 5:10.1111/cas.70492. doi: 10.1111/cas.70492.
    PubMed    
    Abstract available

  71. AYDIN A, Abdulmajeed AS, Bekiroglu FB, Kocak M, et al
    Investigating gender disparities in urological care for non-muscle invasive bladder cancer (NMIBC).
    BJUI Compass. 2026;7:e70245.
    PubMed    
    Abstract available

  72. AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
    ASO Visual Abstract: Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
    Ann Surg Oncol. 2026 Aug 4. doi: 10.1245/s10434-026-20121.
    PubMed    


  73. HORI J, Tokumitsu M, Yamaguchi S, Ishida H, et al
    [Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital].
    Gan To Kagaku Ryoho. 2026;53:407-412.
    PubMed    
    Abstract available

  74. ZHANG S, Li M, Wu Y, Kang Y, et al
    Circ_0001495 promotes bladder cancer progression by regulating miR-1184 via MAPK signaling pathway.
    Mol Biol Rep. 2026;53:1337.
    PubMed    
    Abstract available

  75. TANAKA N, Miyajima A, Kosaka T, Shirotake S, et al
    Editor's Note: Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer.
    Mol Cancer Ther. 2026;25:1410.
    PubMed    


  76. SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
    Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.
    Nat Rev Urol. 2026 Aug 3. doi: 10.1038/s41585-026-01180.
    PubMed    


  77. MALMSTROM PU, Dragomir A, Gardmark T
    Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non-muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer.
    Eur Urol Oncol. 2026 Aug 4:S2588-9311(26)00192-6. doi: 10.1016/j.euo.2026.
    PubMed    


  78. AGHAMIR SMK, Rahimnia R, Taheri D, Ebrahimi M, et al
    Prognostic value of different biomarkers in bladder cancer: protocol for an umbrella review of systematic reviews and meta-analyses.
    BMJ Open. 2026;16:e118810.
    PubMed    
    Abstract available

  79. HAWEZ L, Bergengren O, Ahlberg M, Garmo H, et al
    Suicide risk among urinary bladder cancer patients compared with the standard population: a nationwide study in Sweden.
    Scand J Urol. 2025;60:204-208.
    PubMed    
    Abstract available

  80. MORENO-VEGA A, Zambrano M, Estrada-Virrueta L, Meng X, et al
    FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.
    J Clin Invest. 2026;136:e193280.
    PubMed    
    Abstract available

  81. UGUR R, Demiriz B, Nisli O, Keskin ET, et al
    ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non-Muscle-Invasive Bladder Cancer?
    Ann Surg Oncol. 2026 Aug 1. doi: 10.1245/s10434-026-20351.
    PubMed    


  82. ZENG Z, Hu C, Li Y, Ding B, et al
    Smart nanoplatform targeting the mitochondria-P-gp axis to overcome chemoresistance for synergistic bladder cancer therapy.
    Colloids Surf B Biointerfaces. 2026;268.
    PubMed    
    Abstract available

  83. RUTTEN VC, van Rijen NMA, Franckena M, Robbrecht DGJ, et al
    Real-world Impact of Integrating Comprehensive Geriatric Assessment into Clinical Treatment Decision-making for Older Patients with Bladder Cancer.
    Eur Urol Open Sci. 2026;91:23-31.
    PubMed    
    Abstract available

  84. FUKUHARA H, Shimasaki S, Yamashita E, Kurano Y, et al
    Transurethral laser ablation using 980-nm diode laser for recurrent non-muscle invasive bladder cancer.
    Explor Target Antitumor Ther. 2026;7:1002386.
    PubMed    
    Abstract available

  85. MUSCATELLO LV, Bacci B, Brigandi E, Tugnoli C, et al
    Computer-aided image analysis for PD-L1 assessment in canine urothelial carcinoma.
    Vet J. 2026;318:106758.
    PubMed    
    Abstract available

  86. EINERHAND SMH, Ali H, Wong SQ, van Dorp J, et al
    Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.
    Nat Commun. 2026;17:7679.
    PubMed    
    Abstract available

  87. SUARTZ CV, Azevedo MFD, Brito PHS, Setoue DND, et al
    Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.
    BMC Urol. 2026;26:189.
    PubMed    
    Abstract available

  88. YEH CC, Fan CS, Chen LL, Chua KV, et al
    Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guerin with an enhanced activity against bladder and pancreatic cancers.
    Cancer Immunol Immunother. 2026;75:202.
    PubMed    
    Abstract available

  89. WOO S, Muglia VF, Luk L, Takeuchi M, et al
    What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.
    Cancer Imaging. 2026;26:97.
    PubMed    
    Abstract available

  90. THAI KL, Le PND, Nguyen TT, Ngo XT, et al
    Clinical and imaging predictors of urachal carcinoma: the role of gross hematuria and calcification in a single-center retrospective study.
    BMC Urol. 2026;26:190.
    PubMed    
    Abstract available

  91. MATSUBARA N, Saijo K, Shimizu Y, Okano S, et al
    First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.
    Cancer Sci. 2026;117:2247-2258.
    PubMed    
    Abstract available

  92. VARANASI P, Wengenack N, Steidley DE, Kodali L, et al
    Disseminated Mycobacterium bovis-BCG Infection Following Intravesical BCG Administration in Solid Organ Transplant Recipients.
    Transpl Infect Dis. 2026;28:e70220.
    PubMed    
    Abstract available

  93. TEH A, Sima T, Shinozaki E, Malik R, et al
    A case of canine urothelial carcinoma of the urinary bladder with skull and skeletal metastases.
    Aust Vet J. 2026;104:509-514.
    PubMed    
    Abstract available

  94. LEE T, Akgul M, Fernandez-Pol S, Aron M, et al
    Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.
    Int J Surg Pathol. 2026;34:1483-1488.
    PubMed    
    Abstract available

  95. MITRA S, Shangloo A, Bhatkule MA, Akif S, et al
    Complete Colonic Metaplasia of the Urinary Bladder and Ureters With Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder: A Rare Occurrence.
    Int J Surg Pathol. 2026;34:1630-1635.
    PubMed    
    Abstract available

  96. BUDINA A, Vergara N, Navarro FE, Morrissette JJD, et al
    High-Grade Urothelial Carcinoma with Divergent Prostatic Differentiation Mimicking a Collision Tumor in a Bladder Diverticulum.
    Int J Surg Pathol. 2026;34:1570-1578.
    PubMed    
    Abstract available

  97. GRYPARI IM, Pomoni A, Ganetsou D, Kouroukli O, et al
    True Papillae and Squamous Features in Prostate Carcinoma Represent a Potential Diagnostic Pitfall: Report of 3 Patients.
    Int J Surg Pathol. 2026;34:1610-1615.
    PubMed    
    Abstract available

  98. POLAT UNAL SE, Suren D, Kurtoglu E
    Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.
    Int J Surg Pathol. 2026;34:1586-1590.
    PubMed    
    Abstract available

  99. ILMIAH K, Parengkuan IL, Rahaju AS, Mastutik G, et al
    Bladder Urothelial Neoplasms Profile in Dr. Soetomo General Academic Hospital Surabaya: Retrospective Study during 2013-2023.
    Urologia. 2026;93:384-388.
    PubMed    
    Abstract available

  100. ILKTAC A, Dogan B, Gevher F, Akcay M, et al
    Hematuria-related readmission after transurethral resection of bladder tumor in patients receiving antiplatelet therapy.
    Urologia. 2026;93:370-375.
    PubMed    
    Abstract available

  101. JAVID RAJA IYUB M, Prabhakar P, Pon Avudaiappan A, Sakthivel DK, et al
    Postoperative ileus following radical cystectomy in current urological practice: Incidence and risk factors.
    Urologia. 2026;93:376-383.
    PubMed    
    Abstract available

  102. KITAHAMA K, Inamura K
    Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.
    Histol Histopathol. 2026;41:1483-1491.
    PubMed    
    Abstract available

  103. AL ARMASHI AR, Gong J, Barata P, Brown J, et al
    Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.
    Expert Rev Anticancer Ther. 2026;26:1003-1017.
    PubMed    
    Abstract available

  104. ZHU H, Tan S, Liu X
    Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study.
    Front Oncol. 2026;16:1856699.
    PubMed    
    Abstract available

  105. MATSUSHITA Y, Tamura A, Masuda T, Hasegawa O, et al
    Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.
    World J Urol. 2026;44:566.
    PubMed    
    Abstract available

  106. LI F, Chen C, Ye W, Huang Y, et al
    Shikonin inhibits bladder cancer progression by targeting deoxyribonuclease 2 to suppress reticulon 3-dependent endoplasmic reticulum autophagy.
    Phytomedicine. 2026;160:158682.
    PubMed    
    Abstract available

  107. BURGESS EF, Brown L, McCormack M, Liu L, et al
    Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Cancer Res Commun. 2026 Aug 13. doi: 10.1158/2767-9764.CRC-26-0255.
    PubMed    
    Abstract available

  108. RASKIN Y, Baekelandt F, Decaestecker K, Seront E, et al
    Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.
    World J Urol. 2026;44:560.
    PubMed    
    Abstract available

  109. TANG X, Liu J, Zhao Q, Yang X, et al
    The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients.
    J Clin Med. 2026;15:6124.
    PubMed    
    Abstract available

  110. SUN W, Li Y, Xu M, Guan H, et al
    Oridonin Suppresses Bladder Cancer Growth and Metastasis by Inducing S-Phase Arrest and Apoptosis.
    Int J Mol Sci. 2026;27:6835.
    PubMed    
    Abstract available

  111. SANTINI N, Procino A, Ljubic S, Dermic D, et al
    Extracellular Alpha-Satellite DNA in Human Plasma as a Candidate Biomarker for Bladder Cancer Detection: Preliminary Evidence Using Digital PCR.
    Int J Mol Sci. 2026;27:6834.
    PubMed    
    Abstract available

  112. AKHMETKALIYEV A, Fritz Garcia JHG, Sonnenberg-Riethmacher E, Riethmacher D, et al
    Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.
    Int J Mol Sci. 2026;27:6807.
    PubMed    
    Abstract available

  113. PINTON P
    Structural Misalignment Between Regulatory Definitions of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer and Real-World Clinical Practice.
    Healthcare (Basel). 2026;14:2303.
    PubMed    
    Abstract available

  114. ZHAO F, Vakhrusheva O, Markowitsch SD, Slade KS, et al
    Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. Cells 2025, 14, 570.
    Cells. 2026;15:1363.
    PubMed    
    Abstract available

  115. GOMEZ J, Lakew M, Wilkie H, David B, et al
    Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure.
    Cells. 2026;15:1376.
    PubMed    
    Abstract available

  116. GABRIEL PE, Zhu A, Karim C, Eraky A, et al
    Prognostic Value of Perioperative Circulating Tumor DNA in Pure Urothelial Carcinoma and Histological Subtypes of Bladder Cancer.
    Eur Urol Focus. 2026 Aug 12:S2405-4569(26)00122.
    PubMed    
    Abstract available

  117. BEIJERT IJ, Wever BMM, Moldovan N, van den Burgt Y, et al
    Integrated Methylation and Copy Number Analysis for Noninvasive Bladder Cancer Detection in Urine.
    JCO Precis Oncol. 2026;10:e2500882.
    PubMed    
    Abstract available

  118. SONG L, Meagher M, Saidian A, Salmasi A, et al
    Intravesical Recurrence of Upper Tract Urothelial Carcinoma: Strategies for Prevention.
    Curr Urol Rep. 2026;27:37.
    PubMed    
    Abstract available

  119. CHEN K, Bai Z, Huang Y
    USP5 silencing inhibits the proliferation of bladder cancer cells and induces cell apoptosis and ferroptosis by destabilizing COL14A1 expression.
    Transl Androl Urol. 2026;15:232.
    PubMed    
    Abstract available

  120. WATANABE H, Ishikawa G, Watanabe S, Watanabe S, et al
    Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.
    Transl Androl Urol. 2026;15:234.
    PubMed    
    Abstract available

  121. MIYAKE M
    Rural-urban disparities in high?risk non-muscle?invasive bladder cancer: lessons from the Canadian Bladder Cancer Information System.
    Transl Androl Urol. 2026;15:227.
    PubMed    


  122. ZHOU Y, Yang X, Tian T, Yang B, et al
    Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.
    Front Immunol. 2026;17:1896444.
    PubMed    
    Abstract available

  123. NIE W, Jiang Y, Yao L, Zhu X, et al
    Retraction notice to "Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models" [Heliyon 10 (2024) e39327].
    Heliyon. 2025;12:e44476.
    PubMed    
    Abstract available

  124. GORCZYNSKI A, Tarjan B, Neittaanmaki N
    Deep learning-assisted detection of lymph node metastases in bladder cancer.
    Diagn Pathol. 2026;21:58.
    PubMed    
    Abstract available

  125. SKUPIN PA, Wu S, Orikogbo O, Chadwick SJ, et al
    Treatment Type and Mortality for Black Versus White Patients With Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jul 17:102626. doi: 10.1016/j.clgc.2026.102626.
    PubMed    
    Abstract available

  126. SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
    Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-412
    Eur Urol Oncol. 2026 Aug 11:S2588-9311(26)00219.
    PubMed    


  127. LIU J, Hu M, Chen J, Zu X, et al
    Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.
    Int Immunopharmacol. 2026;187:117273.
    PubMed    
    Abstract available

  128. GUO Y, Ren X, Zhang Z, Cheng H, et al
    The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.
    Cancer Immunol Res. 2026 Aug 11. doi: 10.1158/2326-6066.CIR-25-1445.
    PubMed    
    Abstract available

  129. TIAN J, Li L, Xu L, Liu L, et al
    Effects of self-management interventions on self-care ability and quality of life in patients with urinary ostomy after bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1864061.
    PubMed    
    Abstract available

  130. LI Z, Yan T, Hu C, Lu Z, et al
    Construction and Validation of a Ubiquitination-Related Gene Signature Based on WGCNA and Single-cell RNA Sequencing in Bladder Cancer.
    Curr Med Chem. 2026 Jul 28. doi: 10.2174/0109298673470246260702000813.
    PubMed    
    Abstract available

  131. WU H, Jiang Y, Zhang X, Wang S, et al
    [Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].
    Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1870-1877.
    PubMed    
    Abstract available

  132. LOTAN Y, Margulis V, Woldu S, Allison D, et al
    Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Aug 10:S1078-1439(26)00601.
    PubMed    
    Abstract available

  133. DING Y, Zhu Y, Li J, Chen X, et al
    Mucosa-penetrating NIR-II nanomedicine for precision photoimmunotherapy of bladder cancer.
    Biomaterials. 2026;337:124518.
    PubMed    
    Abstract available

  134. CHEN Y, Wang Z, He C, Yu Z, et al
    KLF6-driven macrophage-to-myofibroblast transition promotes PD-L1-mediated immune evasion in bladder cancer.
    Int Immunopharmacol. 2026;187:117201.
    PubMed    
    Abstract available

  135. MAISCH P, Muhlberger M, Beck A, Schreen W, et al
    Evaluation of Stimulated Raman Histology as a Novel Method for Pathologic Examination of Urothelial Carcinoma With Unprocessed, Fresh Bladder Cancer Tissue.
    Technol Cancer Res Treat. 2026;25:15330338261464295.
    PubMed    
    Abstract available

  136. HU Y, Csuka J, Rajbhandari P, Huang P, et al
    PLA2G2F suppresses ferroptosis through phospholipid remodeling.
    Nat Struct Mol Biol. 2026;33:1147-1157.
    PubMed    
    Abstract available

  137. YANG X, Ding Z, Pengwang Y, Wei Y, et al
    RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.
    Pathol Res Pract. 2026;286:156625.
    PubMed    
    Abstract available

  138. OU M, Ji C, Wen J
    A hypervascular perivascular epithelioid cell tumor of the urinary bladder showing TFE3 immunoreactivity clinically misdiagnosed as paraganglioma in an adolescent patient.
    BMC Urol. 2026;26:195.
    PubMed    
    Abstract available

  139. FLEGAR L, Eisenmenger N, Reimold P, Koch R, et al
    Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022.
    Ann Surg Oncol. 2026;33:8630-8635.
    PubMed    
    Abstract available

  140. DI BELLO F, Gallioli A, Palou J, Breda A, et al
    Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00230.
    PubMed    


  141. KARDOUST PARIZI M, Shariat SF
    Reply to Simone Sforza's Letter to the Editor re: Mehdi Kardoust Parizi, David D'Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00231.
    PubMed    


  142. VRIELING A, Kiebach J, Balvers M, Aben KK, et al
    Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Eur J Nutr. 2026;65:237.
    PubMed    
    Abstract available

  143. PFAIL J, O'Leary C, Fu M, Kaldany A, et al
    The impact of intraoperative ureteral stent omission on postoperative complications during radical cystectomy.
    World J Urol. 2026;44:593.
    PubMed    
    Abstract available

  144. ZEMLA J, Smialek-Bartyzel J, Brzuchacz B, Lekka M, et al
    Lectin-Micropatterned Biointerfaces Regulate Cytoskeletal Organization and Viscoelastic Phenotypes of Bladder Cancer Cells.
    ACS Omega. 2026;11:48215-48229.
    PubMed    
    Abstract available

  145. KHATAMI F, Mohammadi A, Azadmanesh K, Deyhimfar R, et al
    Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.
    Iran J Microbiol. 2026;18:448-459.
    PubMed    
    Abstract available

  146. SHI Y, Luo X, Huang Y, Tan C, et al
    The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients With Bladder Cancer: A Meta-Analysis.
    Clin Med Insights Oncol. 2026;20:11795549261479103.
    PubMed    
    Abstract available

  147. GAN J, Bai X, Zhang A, Lin F, et al
    TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.
    Cancer Sci. 2026 Aug 21. doi: 10.1111/cas.70510.
    PubMed    
    Abstract available

  148. SCARPA RM
    Re: Contieri R, Paciotti M, Uleri A, et al. Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol. 2026;9:404-412.
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00229.
    PubMed    


  149. SUNDRIYAL D, Prasath S, Prakash HS, Swamy AM, et al
    Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting.
    JCO Glob Oncol. 2026;12:e2600219.
    PubMed    
    Abstract available

  150. PRASATH S, Sundriyal D, Harsha SP, Swamy AM, et al
    Feasibility and safety of accelerated MVAC (aMVAC) in geriatric patients with muscle-invasive bladder cancer.
    Med Oncol. 2026;43:248.
    PubMed    
    Abstract available

  151. FU X, Liang Y, Xu B, Huang C, et al
    A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.
    Mater Today Bio. 2026;40:103537.
    PubMed    
    Abstract available

  152. AZARI S, Salmasi A, Stewart T
    Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15.
    Oncologist. 2026 Aug 19:oyag332. doi: 10.1093.
    PubMed    


  153. CRANE K, Bhat KRS, Grivas P, Necchi A, et al
    Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.
    Oncotarget. 2026;17:381-387.
    PubMed    
    Abstract available

  154. WANG W, He J, Wu J, Li W, et al
    Photon-Counting CT With Low-keV Virtual Monoenergetic Images for Detecting Muscle Invasion in Bladder Cancer: A Prospective Study.
    AJR Am J Roentgenol. 2026 Aug 19. doi: 10.2214/AJR.26.35310.
    PubMed    
    Abstract available

  155. LI Z, Li S, Liu Z, Sun Y, et al
    BACE2 Promotes Bladder Cancer Chemoresistance Through Proteolytic Activation of JAG1-Notch Signaling.
    Cancer Innov. 2026;5:e70073.
    PubMed    
    Abstract available

  156. IRANMAHBOUB P, Dave P, Levine J, Wang S, et al
    The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jul 24:102627. doi: 10.1016/j.clgc.2026.102627.
    PubMed    
    Abstract available

  157. HILL-MCMANUS D, Lai Y, Bensimon AG, Young J, et al
    Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.
    J Med Econ. 2026;29:2161-2176.
    PubMed    
    Abstract available

  158. LUO H, Xu C, Huang S, Wang T, et al
    Exploring Long Noncoding RNA CASC11 as a Biomarker for Bladder Cancer Detection.
    Asia Pac J Clin Oncol. 2026 Aug 17. doi: 10.1111/ajco.70139.
    PubMed    
    Abstract available

  159. MANORANJAN B, Zeller S, Price H, Reiner AS, et al
    Clinical and genomic characterization of brain metastasis in bladder cancer.
    J Neurooncol. 2026;179:44.
    PubMed    
    Abstract available

  160. LIU Y, Li Y, Wu T, Hu H, et al
    Comparative Analysis of Disease Burden and Risk Factor Attribution for Urological Cancers in Six High-Growth GBD Regions.
    Arch Esp Urol. 2026;79:1014-1026.
    PubMed    
    Abstract available

  161. ALFIERI AG, Ramirez F, Favre G, Tobia Gonzalez I, et al
    Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Early Radical Cystectomy in Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort From a Latin American Referral Center.
    Arch Esp Urol. 2026;79:915-921.
    PubMed    
    Abstract available

  162. CONTIERI R, Hurle R
    Reply to Pietro scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can
    Eur Urol Oncol. 2026 Aug 17:S2588-9311(26)00218.
    PubMed    


  163. LIN YH
    Beyond Symptom Relief: A Dual-Mechanism Hypothesis Linking Definitive Bladder Outlet Obstruction Relief to Bladder Cancer Control.
    World J Mens Health. 2026 Aug 7. doi: 10.5534/wjmh.260171.
    PubMed    


  164. HE Q, Jiang Z, Jiang C, Tu X, et al
    Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER.
    World J Urol. 2026;44:575.
    PubMed    
    Abstract available

  165. CHEN C, Zheng H, Luo Y, Kong Y, et al
    Corrigendum to SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1? ?and lymph node metastasis in bladder cancer.
    J Clin Invest. 2026;136:e210810.
    PubMed    


  166. HUANG CS, Tung KH, Wu YS, Yu CP, et al
    Association of Postoperative Antidepressant and Anxiolytic Exposure With Overall Survival Following Radical Cystectomy for Bladder Cancer.
    Psychooncology. 2026;35:e70581.
    PubMed    
    Abstract available

  167. LI R, Zhao A, Zhuang Q, Peng L, et al
    An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.
    Adv Sci (Weinh). 2026 Aug 17:e77241. doi: 10.1002/advs.77241.
    PubMed    
    Abstract available

  168. BURGESS EF, Elom H, Brown LC, McCormack M, et al
    The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.
    BJUI Compass. 2026;7:e70274.
    PubMed    


  169. XU H, Han X, Zhang Y, Liu X, et al
    When uncertainty becomes guilt: The moralisation of home urinary stoma care after bladder cancer surgery in China.
    Soc Sci Med. 2026;407:119667.
    PubMed    
    Abstract available

  170. ANDREASEN TG, Strandgaard T, Divita TJ, Young-Halvorsen K, et al
    Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2026;91:74-83.
    PubMed    
    Abstract available

  171. WANG X, Li Z, Zhang B
    Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.
    Front Oncol. 2026;16:1821922.
    PubMed    
    Abstract available

  172. MERCIER J, Cornillon P, Barthelemy P, Leon P, et al
    Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group.
    Crit Rev Oncol Hematol. 2026;225:105505.
    PubMed    
    Abstract available

  173. YUAN Q, Xing X, Ma Z, Shang P, et al
    Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis.
    Radiother Oncol. 2026;222:111697.
    PubMed    
    Abstract available

  174. LIU X, Fu K, Xiong L, Liu X, et al
    Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases.
    Urol Oncol. 2026;44:412-421.
    PubMed    
    Abstract available

  175. NANDWANA D, Siva J, Davis L, Sindhani M, et al
    Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.
    Urol Oncol. 2026;44:211-222.
    PubMed    
    Abstract available

  176. MOHAMED T, Mohamed H, Deameh MG, Irshid BAB, et al
    Ileal conduit vs. orthotopic ileal neobladder after radical cystectomy: Systematic review and meta-analysis of long-term renal function.
    Urol Oncol. 2026;44:147-157.
    PubMed    
    Abstract available

  177. FAYOLLE E, Baudot A, Chaneliere-Sauvant AF, Favier E, et al
    Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.
    BMC Geriatr. 2026;26:1067.
    PubMed    
    Abstract available

  178. UCHINO T, Miura M, Shingu C, Shin T, et al
    Ultrasound versus nerve stimulation-guided interadductor approach for obturator nerve block: evaluation of injectate spread into the obturator canal in a randomized controlled trial.
    BMC Anesthesiol. 2026;26:501.
    PubMed    
    Abstract available

  179. COLLINS K, Cheng L
    FGFR3-Altered Urothelial Carcinoma: Clinicopathologic Observations With Emphasis on Variant Histology.
    Lab Invest. 2026;106:106133.
    PubMed    
    Abstract available

  180. XIN S, Li G, Yang X, Su J, et al
    Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value.
    Clin Exp Med. 2026;26:298.
    PubMed    
    Abstract available

  181. CHENG L, Tan HM, Lopez-Beltran A, Montironi R, et al
    Urothelial Carcinoma in Children and Young Adults is Characterized by Higher Frequency of HRAS Mutations and Lower Prevalence of TERT Promoter and FGFR3 Mutations.
    Am J Surg Pathol. 2026;50:999-1006.
    PubMed    
    Abstract available

  182. SCARPA RM
    Re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9:652-9.
    Eur Urol Oncol. 2026 Aug 28:S2588-9311(26)00235.
    PubMed    


  183. GUNDOGAR O, Bektas S, Arslan B, Akbas P, et al
    TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.
    In Vivo. 2026;40:3137-3145.
    PubMed    
    Abstract available

  184. WANG MH, Pan MR, Hung YH
    Inhibition of Cyclin-dependent Kinase Counteracts Neuron-promoted Bladder and Endometrial Tumorigenesis: A Systematic Analysis.
    In Vivo. 2026;40:2753-2765.
    PubMed    
    Abstract available

  185. YAMASHITA S, Yasuhara M, Higuchi M, Iwagami S, et al
    Perioperative and Oncological Outcomes of Robot-assisted Versus Open Radical Cystectomy: A Propensity Score-matched Multicenter Study from Japan.
    In Vivo. 2026;40:3098-3105.
    PubMed    
    Abstract available

  186. CHEN HX, Liu SL, Huang CP, Hsu YC, et al
    Inflammatory Myofibroblastic Tumor of the Urinary Bladder Presenting as a Radiological cT3 Mass: A Case Report and Narrative Review of 89 Cases.
    In Vivo. 2026;40:3191-3204.
    PubMed    
    Abstract available

  187. SMITH AK, Wittmann D, Emodi K, Dykstra G, et al
    Difficult conversations in bladder cancer survivorship: Integrating mental health and intimacy into routine urologic care.
    Bladder Cancer. 2026;12:23523735261480430.
    PubMed    
    Abstract available

  188. ZHANG B, Chen Y, Wang Y, Liu Y, et al
    Summary of the best evidence for whole-course nutritional management of bladder cancer.
    Front Nutr. 2026;13:1916117.
    PubMed    
    Abstract available

  189. MIRZA W, Hussain K, Anwaar A, Shaikh A, et al
    ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.
    World J Urol. 2026;44:610.
    PubMed    
    Abstract available

  190. LI H, Cheng L, Lu X, Dong H, et al
    DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT.
    Adv Sci (Weinh). 2026 Aug 27:e77435. doi: 10.1002/advs.77435.
    PubMed    
    Abstract available

  191. QIN S, Hong Y, Cheng J, Lv Q, et al
    Spectral CT-derived quantitative imaging parameters combined with inflammatory markers for exploratory preoperative grading of bladder cancer.
    Front Oncol. 2026;16:1892226.
    PubMed    
    Abstract available

  192. WANG M, Lin M, Wang Y
    CTHRC1(+) cancer associated-fibroblasts promotes malignant progression of bladder cancer cells via inducing an immunosuppressive tumor microenvironment.
    Front Immunol. 2026;17:1898002.
    PubMed    
    Abstract available

  193. AZEVEDO MFD, Brito PHS, Kallas-Silva L, Liebl B, et al
    Extended Versus Non-Extended Lymphadenectomy in Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    J Surg Oncol. 2026 Aug 26. doi: 10.1002/jso.70334.
    PubMed    
    Abstract available

  194. ARIKAN MG, Arda E, Izol V, Yilmaz H, et al
    Outcomes and Predictive Factors for Gynecologic Organ Involvement in Radical Cystectomy for Female Bladder Cancer Patients: A Multicenter Retrospective Cohort Study.
    Medicina (Kaunas). 2026;62:1609.
    PubMed    
    Abstract available

  195. LI G, Li D, Lan B, Cheng Y, et al
    Iron Oxide Nanozyme for Magnetothermal Activation of ER-TRPV1 Enables Efficient Intravesical Therapy of Bladder Cancer.
    Int J Mol Sci. 2026;27:7475.
    PubMed    
    Abstract available

  196. CAMPANELLI G, Parkhomovsky N, Mak CK, Yang C, et al
    MTA1 Regulates EMT and BRAF Signaling Networks in Canine Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:7272.
    PubMed    
    Abstract available

  197. ZHANG D, Ren H, Bai Y, Han P, et al
    Integrated Mendelian Randomization and Single-Cell Transcriptomics Reveal T Cell Immune Mechanisms in Systemic Lupus Erythematosus-Bladder Cancer Comorbidity.
    Life (Basel). 2026;16:1381.
    PubMed    
    Abstract available

  198. CROITOR A, Cadariu-Brailoiu V, Zbircea AD, Bardan R, et al
    Hyperthermic Intravesical Chemotherapy as a Bladder-Sparing Alternative to BCG in the Management of Non-Muscle-Invasive Bladder Cancer: A Systematic Review of Oncological Outcomes in the Era of BCG Shortage.
    J Clin Med. 2026;15:6352.
    PubMed    
    Abstract available

  199. LIU S, Duan L, Wei S
    Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis.
    Curr Issues Mol Biol. 2026;48:825.
    PubMed    
    Abstract available

  200. VANDER STICHELE A, Van Cleynenbreugel B
    Optical Spectroscopy and Spectral Imaging for Bladder Cancer Detection and Characterisation: A Scoping Review of Diagnostic Evidence and Translational Readiness.
    Diagnostics (Basel). 2026;16:2561.
    PubMed    
    Abstract available

  201. TURGALIYEV A, Konovalov R, Borissenko A, Riethmacher D, et al
    Mechanobiology of Matricellular Proteins in Bladder Cancer: A Narrative Review and Bioinformatics Analysis.
    Biomolecules. 2026;16:1191.
    PubMed    
    Abstract available

  202. SILVANI C, Abdollah F
    Reply: Incarcerated Patients Present With More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2026 Aug 20:101097UPJ0000000000001062.
    PubMed    


  203. UNE M, Yamamoto S, Fuse H, Yoneoka Y, et al
    Older Age Does Not Have an Impact on Postoperative Complication Risk Following Transurethral Resection of the Bladder Tumor.
    Curr Oncol. 2026;33:457.
    PubMed    
    Abstract available

  204. DI LORENZO G, Di Lorenzo S, Verde A, Strianese O, et al
    Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series.
    Curr Oncol. 2026;33:456.
    PubMed    
    Abstract available

  205. MUNOZ RA, Medina LG, Kim JS, Supernaw A, et al
    Single-Stoma Cutaneous Ureterostomy After Radical Cystectomy: A Contemporary Narrative Review.
    Curr Oncol. 2026;33:455.
    PubMed    
    Abstract available

  206. HUANG KH, Liu YY, Wu CC, Chen CL, et al
    Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.
    Biosensors (Basel). 2026;16:445.
    PubMed    
    Abstract available

  207. DONG Y, Xu C, Yan B, Mou S, et al
    Quantitative and Targeted Regulation of Ferroptosis in Bladder Cancer: Preclinical Study.
    J Cell Mol Med. 2026;30:e71333.
    PubMed    
    Abstract available

  208. YANG W, Yao L, Wan L, Zhuang C, et al
    CircFut8 Suppresses Bladder Cancer by Modulating SRSF9-Dependent Pre-mRNA Splicing.
    J Gene Med. 2026;28:e70108.
    PubMed    
    Abstract available

  209. GRIEBSCH I, Shrestha S, Gotay CC, Gore JL, et al
    Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review.
    Oncol Ther. 2026 Aug 25. doi: 10.1007/s40487-026-00463.
    PubMed    
    Abstract available

  210. NOSSING C, Ertl IE, Englinger B
    Rethinking EZH2 Inhibition: A Priming Strategy for EGFR-targeted Therapy in Bladder Cancer.
    Eur Urol Oncol. 2026 Aug 25:S2588-9311(26)00236.
    PubMed    


  211. KAMIYAMA Y, Abe S, Hoshiyama A, Nishikawa Y, et al
    Initial Experience With a Step-Specific Reconstructive Strategy During Robot-Assisted Radical Cystectomy Using the da Vinci SP System.
    Asian J Endosc Surg. 2026;19:e70372.
    PubMed    
    Abstract available

  212. LOBO A, Cheng L
    Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System.
    Endocr Pathol. 2026;37:36.
    PubMed    
    Abstract available

  213. GAO J, Ji CX, Ren C, Hines J, et al
    Rapid normal fibroblast-tumor crosstalk promotes cancer-associated fibroblast-like activation and attenuates mitomycin C cytotoxicity in bladder cancer.
    J Cell Commun Signal. 2026;20:e70110.
    PubMed    
    Abstract available

  214. FUKIAGE Y, Okubo N, Taga M, Sato Y, et al
    Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities.
    Front Mol Biosci. 2026;13:1898769.
    PubMed    
    Abstract available

  215. CHEN H, Lin Y, Xue Z, Qie Y, et al
    Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.
    Front Immunol. 2026;17:1929760.
    PubMed    
    Abstract available

  216. DIAO S, Zhao J, Liu X
    A locally deployed large language model for pathology-informed and nurse-reviewed communication support in bladder cancer immunotherapy.
    Front Med (Lausanne). 2026;13:1903690.
    PubMed    
    Abstract available

  217. SOOD A, Martini A, Genitiano P, Rauf M, et al
    Combination treatment with intravesical interferon-alpha gene therapy and an oral pan-ErbB receptor family blocker improves survival in mice with bladder cancer.
    Front Mol Biosci. 2026;13:1804161.
    PubMed    
    Abstract available

  218. LIJNEN RAG, Vierling ML, Ringia JB, Hendricksen K, et al
    Clinical impact of routine second?opinion reading of [(1)(8)F]FDG?PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network.
    Eur J Nucl Med Mol Imaging. 2026 Aug 25. doi: 10.1007/s00259-026-08145.
    PubMed    
    Abstract available

  219. BAJDAK-RUSINEK K, Wierzbinka M, Sundararajan V, Sieron L, et al
    ESRP2-dependent CD44 isoform switching is functionally linked to epithelial-mesenchymal plasticity in bladder cancer.
    Biochim Biophys Acta Gene Regul Mech. 2026;1869:195180.
    PubMed    
    Abstract available

  220. DURANT AM, Steffen J, Huelster H, Kaimakliotis H, et al
    Evaluating Circulating DNA as a Prognostic Biomarker in Bladder Cancer Subtypes: A Preliminary Short Report.
    Clin Genitourin Cancer. 2026 Jul 30:102635. doi: 10.1016/j.clgc.2026.102635.
    PubMed    


  221. TEIXEIRA EG, Torres LAF, Defante MLR, de Azevedo FM, et al
    Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026;44:643-651.
    PubMed    
    Abstract available

  222. SHINOHARA M, Narita T, Hamaya T, Ichiyama T, et al
    A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.
    Urol Oncol. 2026;44:633-642.
    PubMed    
    Abstract available

  223. MERCINELLI C, Basile G, Pastorino GL, Cigliola A, et al
    Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.
    Clin Genitourin Cancer. 2026;24:102638.
    PubMed    
    Abstract available

  224. ALI-EL-DEIN B, Abdelgawad M, Abdel-Rahim M, Gomaa IM, et al
    Relationship between concentration of heavy metals in bladder cancer tissue and molecular types using luminal GATA3 and basal cytokeratin 5/6 markers.
    J Trace Elem Med Biol. 2026;97:127944.
    PubMed    
    Abstract available

  225. PENG B, Wang Y, Li H, Zhuang C, et al
    Lipopolysaccharide promotes bladder cancer immunosuppression by disrupting the Tfh/Tfr balance through TLR4 signaling.
    Am J Transl Res. 2026;18:5612-5622.
    PubMed    
    Abstract available

  226. COHEN IE, Bruzzi HF, Gontijo GCES, de Carvalho MFSS, et al
    Real-world efficacy and sequential therapy patterns after avelumab maintenance in metastatic urothelial carcinoma: a Brazilian multicenter retrospective cohort study.
    Cancer Treat Res Commun. 2026;48:101368.
    PubMed    
    Abstract available

  227. HARA T, Tobe T, Ueki H, Wakita N, et al
    Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.
    Int J Clin Oncol. 2026;31:2025-2032.
    PubMed    
    Abstract available

  228. SONGLIN L, Yunxun L, Peiyu H, Wen H, et al
    A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab.
    BMC Urol. 2026;26:210.
    PubMed    
    Abstract available

  229. KOBARI Y, Nakajima N, Saito A, Katsurayama N, et al
    Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2026;46:4453-4460.
    PubMed    
    Abstract available

  230. LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
    INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
    BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
    PubMed    
    Abstract available

  231. CHEN Y, Yue Z
    Incidence is not surveillance yield: interpreting metachronous upper tract urothelial carcinoma risk after non-muscle-invasive bladder cancer.
    BJU Int. 2026 Aug 11. doi: 10.1111/bju.70429.
    PubMed    


  232. IBRAHIM Y, Ribeiro L, Spazzapan M, Gad M, et al
    Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.
    BJU Int. 2026;138:449-455.
    PubMed    
    Abstract available

  233. CELLA L, Contieri R, Paciotti M, Fasulo V, et al
    Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.
    BJU Int. 2026 Aug 17. doi: 10.1111/bju.70404.
    PubMed    
    Abstract available

  234. MIYAJIMA K, Miszczyk M, Roessler N, Inoue S, et al
    Diet and risk of bladder cancer: a systematic review of epidemiological evidence.
    BJU Int. 2026 Aug 23. doi: 10.1111/bju.70435.
    PubMed    
    Abstract available

  235. ZHANG L, Liu Z, Ding Y, Sun J, et al
    Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
    Br J Cancer. 2026;135:559-567.
    PubMed    
    Abstract available

  236. WALKER CH, Jabalameli N, Rais-Bahrami S
    Radiomic phenotypes in nonmuscle-invasive bladder cancer: A precision biomarker guiding therapy.
    Cancer. 2026;132:e70563.
    PubMed    
    Abstract available

  237. PAPADIMITRIOU MA, Pilala KM, Panoutsopoulou K, Soureas K, et al
    Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification.
    Eur J Cancer. 2026;246:116987.
    PubMed    
    Abstract available

  238. GALSKY MD, Necchi A
    Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.
    Eur Urol. 2026 Jul 27:S0302-2838(26)02271-2. doi: 10.1016/j.eururo.2026.
    PubMed    
    Abstract available

  239. MATSUSHITA Y, Kita Y, Mukai S, Joraku A, et al
    Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
    Int J Urol. 2026;33:e70584.
    PubMed    
    Abstract available

  240. KIKUCHI E, Tokumaru J, Kawai D, Ide R, et al
    Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.
    Int J Urol. 2026;33:e70565.
    PubMed    
    Abstract available

  241. WATANABE R
    Editorial Comment to "Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study".
    Int J Urol. 2026;33:e70604.
    PubMed    


  242. WAKITA N, Hara T, Tobe T, Ueki H, et al
    Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
    Int J Urol. 2026;33:e70614.
    PubMed    
    Abstract available

  243. ALMULLA AF, Zhang Y, Maes M
    Editorial Comment on "Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression": Rethinking the Tryptophan-Kynurenine Pathway in Urological Cancer Immunotherapy.
    Int J Urol. 2026;33:e70606.
    PubMed    


  244. FERREIRA WAS, Marchi FA, Vitiello GAF, Villacis RAR, et al
    Cathepsin V (CTSV) Shapes the Epigenetic-Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker.
    Int J Urol. 2026;33:e70609.
    PubMed    
    Abstract available

  245. ZHANG B, Wang C, Yang S, Li X, et al
    A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.
    Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275.
    PubMed    
    Abstract available

  246. CHEN Y, An W, Qu R, Chen C, et al
    Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients.
    Int Urol Nephrol. 2026 Aug 28. doi: 10.1007/s11255-026-05316.
    PubMed    
    Abstract available

  247. CHAI Y, Zhang L, Zhou Y, Dai J, et al
    Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis.
    Int Urol Nephrol. 2026 Aug 26. doi: 10.1007/s11255-026-05360.
    PubMed    
    Abstract available

  248. RYTZ MA, Hussung S, Frehner L, Beyer J, et al
    LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.
    Int Urol Nephrol. 2026 Aug 25. doi: 10.1007/s11255-026-05351.
    PubMed    
    Abstract available

  249. YOUSSEF HMK, Ibrahim EH, Hasan A, Samman A, et al
    Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients.
    Int Urol Nephrol. 2026;58:3557-3566.
    PubMed    
    Abstract available

  250. BAKHSH A, Abdullah S, Farghal DM, Badawi AS, et al
    Association of electronic cigarette and conventional smoking with urogenital cancers: NHIS analysis.
    Int Urol Nephrol. 2026;58:3681-3688.
    PubMed    
    Abstract available

  251. GABRIEL PE, Zhu A, Xylinas E, Sfakianos JP, et al
    Beyond the NMIBC-MIBC Dichotomy: Integrating Molecular Biomarkers into Bladder Cancer Risk Stratification.
    J Urol. 2026 Aug 11:101097JU0000000000005255. doi: 10.1097/JU.0000000000005255.
    PubMed    


  252. JOFFE BI, Pingle SR, Laplaca C, Christin JR, et al
    Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.
    J Urol. 2026 Aug 26:101097JU0000000000005278. doi: 10.1097/JU.0000000000005278.
    PubMed    
    Abstract available

  253. GAO Y, Chen C, Sun R, Yao Y, et al
    LncRMRP drives bladder cancer invasion via a lactylation-driven positive feedback circuit.
    Oncogene. 2026 Jul 30. doi: 10.1038/s41388-026-03927.
    PubMed    
    Abstract available

  254. ZHAN Y, Zhu C, Li Y, Wen C, et al
    Transcription factor EN1 governs a lipogenic USP18-ACLY axis to drive bladder cancer malignancy.
    Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03910.
    PubMed    
    Abstract available

  255. XIONG R, Wang M, Du J, Chai B, et al
    USP15-mediated deubiquitination of FIS1 impairs mitochondrial function and sensitizes bladder cancer cells to radiotherapy.
    Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03918.
    PubMed    
    Abstract available

  256. ZHU D, Wan X, Huang H, Chen X, et al
    [Corrigendum] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell?like side population cells.
    Oncol Rep. 2026;56:171.
    PubMed    
    Abstract available

  257. ROBERSON DS, Wang MK, McLeay Ii MT, Wei N, et al
    A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.
    Urology. 2026;214:35-40.
    PubMed    
    Abstract available

  258. GOLOMB D, Simard S, Eisner A, Avda Y, et al
    Fear and Health Behavior: The Association Between Fear of Cancer Recurrence and Smoking Cessation.
    Urology. 2026;214:87-92.
    PubMed    
    Abstract available

  259. ZUBAIR Z, Milenkovski B, Leon AR, Mian M, et al
    "I Don't Feel I Have a Lot of Training in Mental Health...": A Qualitative Assessment of Provider Perspectives on Behavioral Health Support for Patients Undergoing Cystectomy.
    Urology. 2026;214:55-60.
    PubMed    
    Abstract available

  260. TAMBARO R, Calvanese G, Muto A, Formisano L, et al
    Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
    BMC Cancer. 2026;26:956.
    PubMed    
    Abstract available

  261. WANG T, Jiang X
    Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
    BMC Cancer. 2026;26:997.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum


;